Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (151-160 of 242) with videos related to

Pageof 25
Sort By:
Annals of Surgical Oncology|March 4, 2018
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional StudyShinkichi Takamori, Gouji Toyokawa, Mototsugu Shimokawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2020
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA TrialMakoto Nishio, Tatsuya Yoshida, Toru Kumagai, et al.
Anticancer Research|September 16, 2016
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung AdenocarcinomaGouji Toyokawa, Kenichi Taguchi, Makoto Edagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2011
S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706)Yukito Ichinose, Takashi Seto, Tomonari Sasaki, et al.
Drugs in R&D|December 17, 2020
Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I StudyAkira Ono, Haruyasu Murakami, Takashi Seto, et al.
Future Oncology (London, England)|September 25, 2025
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic <i>EGFR</i>-mutated NSCLCKazumi Nishino, Takashi Seto, Makoto Nishio, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2020
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA studySeiji Niho, Tatsuya Yoshida, Tetsuo Akimoto, et al.
Clinical Lung Cancer|May 9, 2020
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerYoshimasa Shiraishi, Junji Kishimoto, Kentaro Tanaka, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|June 5, 2014
Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancerTomoyoshi Takenaka, Mitsuhiro Takenoyama, Masafumi Yamaguchi, et al.
The Journal of Medical Investigation : JMI|September 29, 2017
Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocolShinji Takeuchi, Toshinori Murayama, Kenichi Yoshimura, et al.
Pageof 25

Showing results (151-160 of 242) with videos related to

Sort By:
Pageof 25
Annals of Surgical Oncology|March 4, 2018
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional StudyShinkichi Takamori, Gouji Toyokawa, Mototsugu Shimokawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 28, 2020
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA TrialMakoto Nishio, Tatsuya Yoshida, Toru Kumagai, et al.
Anticancer Research|September 16, 2016
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung AdenocarcinomaGouji Toyokawa, Kenichi Taguchi, Makoto Edagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2011
S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706)Yukito Ichinose, Takashi Seto, Tomonari Sasaki, et al.
Drugs in R&D|December 17, 2020
Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I StudyAkira Ono, Haruyasu Murakami, Takashi Seto, et al.
Future Oncology (London, England)|September 25, 2025
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic <i>EGFR</i>-mutated NSCLCKazumi Nishino, Takashi Seto, Makoto Nishio, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2020
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA studySeiji Niho, Tatsuya Yoshida, Tetsuo Akimoto, et al.
Clinical Lung Cancer|May 9, 2020
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerYoshimasa Shiraishi, Junji Kishimoto, Kentaro Tanaka, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|June 5, 2014
Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancerTomoyoshi Takenaka, Mitsuhiro Takenoyama, Masafumi Yamaguchi, et al.
The Journal of Medical Investigation : JMI|September 29, 2017
Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocolShinji Takeuchi, Toshinori Murayama, Kenichi Yoshimura, et al.
Pageof 25